Johnson & Johnson logo
Johnson & Johnson JNJ
$ 205.3 -0.07%

Quarterly report 2025-Q3
added 10-22-2025

report update icon

Johnson & Johnson Income Statement 2011-2025 | JNJ

Annual Income Statement Johnson & Johnson

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

379 B 404 B 420 B 445 B - 394 B 343 B 298 B 287 B - 287 B 253 B 188 B 168 B

Shares

2.41 B 2.53 B 2.63 B 2.63 B - 2.63 B 2.63 B 2.63 B 2.77 B - 2.82 B 2.81 B 2.86 B 2.78 B

Historical Prices

157 159 159 169 151 137 118 124 99.6 86.4 85.5 72.8 54 48.7

Net Income

14.1 B 35.2 B 4.46 B 14.7 B - 15.1 B 15.3 B 16.5 B 15.4 B - 16.3 B 13.8 B 9.67 B 13.3 B

Revenue

88.8 B 85.2 B 20 B 82.6 B - 82.1 B 81.6 B 71.9 B 70.1 B - 74.3 B 71.3 B 65 B 61.6 B

Cost of Revenue

27.5 B 26.6 B 23.4 B 28.4 B - 27.6 B 27.1 B 25.4 B - - - - - -

Gross Profit

61.4 B 58.6 B 13.8 B 54.2 B - 54.6 B 54.6 B 50.2 B 48.6 B - 51.6 B 49.7 B 44.8 B 42.8 B

Operating Income

- - - - - - - - - - 21.6 B 16.4 B 15 B 17.7 B

Interest Expense

-4.69 B -6.63 B 183 M 201 M - 318 M 1 B 934 M 552 M - 533 M 482 M 532 M 455 M

EBITDA

7.34 B 7.49 B 7.39 B 7.23 B - 24.3 B 24.9 B 23.6 B 22.9 B - 24.5 B 19.6 B 15.5 B 19.9 B

Operating Expenses

- - - - - 37.3 B 36.6 B 30.4 B 29.4 B - 31 B 34.2 B 32.4 B 25.8 B

General and Administrative Expenses

22.9 B 21.5 B 20.1 B 22.1 B - - - - - - - - - -

All numbers in USD currency

Quarterly Income Statement Johnson & Johnson

2025-Q3 2025-Q2 2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

2.41 B 2.41 B 2.41 B 2.41 B 2.41 B 2.41 B 2.52 B 2.6 B 2.61 B - 2.63 B 2.63 B 2.63 B - 2.63 B 2.63 B 2.63 B - 2.63 B 2.63 B 2.63 B - 2.64 B 2.65 B 2.66 B - 2.68 B 2.68 B 2.68 B - 2.68 B 2.69 B 2.71 B - 2.73 B 2.75 B 2.76 B - 2.77 B 2.77 B 2.78 B - 2.81 B 2.83 B 2.83 B - 2.82 B 2.81 B 2.79 B - 2.76 B 2.75 B 2.74 B - 2.74 B 2.74 B 2.74 B

Net Income

5.15 B 5.54 B 11 B 2.69 B 4.69 B 3.26 B 26 B 5.14 B -68 M - 4.46 B 4.81 B 5.15 B - 3.67 B 6.28 B 6.2 B - 3.55 B 3.63 B 5.8 B 4.01 B 1.75 B 5.61 B 3.75 B 3.04 B 3.93 B 3.95 B 4.37 B -10.7 B 3.76 B 3.83 B 4.42 B 3.22 B 4.27 B 4 B 4.46 B - 3.36 B 4.52 B 4.32 B 2.52 B 4.75 B 4.33 B 4.73 B 3.52 B 2.98 B 3.83 B 3.5 B 2.57 B 2.97 B 1.41 B 3.91 B 1.94 B 3.2 B 2.78 B 3.48 B

Revenue

24 B 23.7 B 21.9 B 22.5 B 22.4 B 21.4 B 21.4 B 21.5 B 20.9 B - 20 B 24 B 23.4 B - 23.3 B 23.3 B 22.3 B - 21.1 B 18.3 B 20.7 B 20.7 B 20.7 B 20.6 B 20 B 20.4 B 20.3 B 20.8 B 20 B 20.2 B 19.6 B 18.8 B 17.8 B - - - - - - - - - 18.5 B 19.5 B 18.1 B - 17.6 B 17.9 B 17.5 B - 17.1 B 16.5 B - - - - -

Cost of Revenue

7.3 B 7.63 B 7.36 B 6.96 B 6.87 B 6.51 B 6.61 B 6.46 B 6.69 B - 6.17 B 7.92 B 7.6 B - 7.25 B 7.59 B 7.06 B - 6.97 B 6.58 B 7.06 B - 6.87 B 6.94 B 6.62 B - 6.59 B 6.93 B 6.61 B - 6.92 B - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

16.7 B 16.1 B 14.5 B 15.5 B 15.6 B 14.9 B 14.7 B 15.1 B 14.2 B - 13.8 B 16.1 B 15.8 B - 16.1 B 15.7 B 15.3 B - 14.1 B 11.8 B 13.6 B 13.6 B 13.9 B 13.6 B 13.4 B 13.4 B 13.8 B 13.9 B 13.4 B 12.9 B 12.7 B 13 B 12.4 B 12.1 B 12.3 B 13.1 B 12.2 B - 11.9 B 12.4 B 12.1 B 12.4 B 13.1 B 13.5 B 12.7 B 12.4 B 12.2 B 12.4 B 12 B 11.6 B 11.5 B 11.3 B 11.2 B 10.6 B 10.9 B 11.4 B 11.4 B

Operating Income

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 5.83 B - 7.05 B 5.88 B 5.65 B - 3.87 B 5.02 B 4.48 B - 3.82 B 2.66 B 5.13 B - 4.65 B 3.54 B 4.73 B

Interest Expense

478 M -107 M 7.32 B -1.8 B -653 M -2.4 B -499 M 384 M 212 M - 51 M 38 M 10 M - 20 M 40 M 63 M - 44 M 45 M 25 M - 48 M 83 M 102 M - 243 M 253 M 259 M - 229 M 227 M 204 M - 192 M 190 M 160 M - 123 M 131 M 138 M - 130 M 128 M 136 M - 105 M 118 M 125 M - 135 M 143 M 147 M - 134 M 129 M 125 M

EBITDA

- - - - - - - - - - 1 B 1.1 B 1.77 B - 5.55 B 1.2 B 1.89 B - 5.29 B 3.47 B 1.75 B - 5.19 B 3.47 B 1.76 B - 5.19 B 3.46 B 1.75 B - 3.77 B 2.06 B 912 M - 2.7 B 1.79 B 891 M - 2.71 B 1.78 B 6.72 B - 9.96 B 7.84 B 6.66 B - 6.87 B 7.05 B 5.52 B - 6.46 B 4.28 B 5.9 B - 6.96 B 5.07 B 5.48 B

General and Administrative Expenses

5.92 B 5.89 B 5.11 B 5.48 B 5.68 B 5.26 B 5.4 B 5.4 B 4.91 B - 4.98 B 6.23 B 5.94 B - 6 B 6.07 B 5.43 B - 5.43 B 4.99 B 5.2 B - 5.37 B 5.55 B 5.22 B - 5.54 B 5.74 B 5.26 B - 5.42 B 5.29 B 4.76 B - 4.77 B 5.18 B 4.69 B - 5.08 B 5.38 B 4.85 B - 5.47 B 5.48 B 5.18 B - 5.31 B 5.38 B 5.22 B - 5.23 B 4.96 B 5.02 B - 5.24 B 5.22 B 5.06 B

All numbers in USD currency

The income statement is one of the three key financial reports of a company Johnson & Johnson (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
AC Immune SA AC Immune SA
ACIU
$ 2.8 2.19 % $ 229 M schweizSchweiz
ADiTx Therapeutics ADiTx Therapeutics
ADTX
$ 2.49 -11.39 % $ 32.8 K usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 4.59 -4.08 % $ 98.1 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 12.12 -1.58 % $ 3.74 B usaUSA
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 5.37 -20.68 % $ 194 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
argenx SE argenx SE
ARGX
$ 919.62 2.76 % $ 25 B niderlandNiderland
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 203.0 -3.72 % $ 5 B danmarkDanmark
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 4.64 -0.32 % $ 92 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.36 2.73 % $ 8.08 B australiaAustralia
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 3.29 -1.5 % $ 908 M israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 54.27 -1.38 % $ 10.3 B usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
AbbVie AbbVie
ABBV
$ 224.99 -0.01 % $ 398 B usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
BioNTech SE BioNTech SE
BNTX
$ 96.22 -1.21 % $ 27.2 B germanyGermany
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 18.75 -0.48 % $ 2.76 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.92 -7.01 % $ 4.87 M usaUSA
Biogen Biogen
BIIB
$ 179.76 1.11 % $ 26.2 B usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 23.52 -2.22 % $ 1.94 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.45 -0.72 % $ 1.02 B canadaCanada
Cabaletta Bio Cabaletta Bio
CABA
$ 2.37 -2.67 % $ 2.77 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA